AllJournalThesisConferenceNewspaperPatentStandardYear BookBook|ResearcherProject
all languages  Chinese Only  Other Languages
Author:Tapan Saikia , Pankaj Malhotra ...
Data Source:[J].Indian Journal of Hematology and Blood Transfusion(IF 0.25), 2017, Vol.33 (1), pp.15-21Springer
Abstract:Abstract(#br)The science of multiple myeloma (MM) and related plasma cell disorders is rapidly evolving with increased understanding of the disease biology and recent approval of the newer drugs widening the therapeutic armamentarium. Despite multiple international guidelines reg...
Author:Tapan Saikia , Sushmita Ghoshal ...
Data Source:[J].The Lancet Oncology(IF 25.117), 2019, Vol.20 (4), pp.e218-e223Elsevier
Abstract:Summary(#br)The Choosing Wisely India campaign was an initiative that was established to identify low-value or potentially harmful practices that are relevant to the Indian cancer health-care system. We undertook a multidisciplinary framework-driven consensus process to identify ...
Author:Tapan Saikia , Kunal Oswal ...
Data Source:[J].The Lancet Oncology(IF 25.117), 2019, Vol.20 (11), pp.e637-e644Elsevier
Abstract:Summary(#br)Efforts are being made to scale up human papillomavirus (HPV) vaccination for adolescent girls in India. Bivalent and quadrivalent HPV vaccines were licensed in the country in 2008, and a nonavalent vaccine was licensed in 2018. Demonstration projects initiated in And...
Author:... Sadhana Kannan , Reena Nair , Tapan Saikia
Data Source:[J].International Journal of Hematology(IF 1.681), 2016, Vol.103 (3), pp.292-298Springer
Abstract:Abstract(#br)We compared the lomustine, cytarabine, cyclophosphamide and etoposide (LACE) and BCNU, etoposide, cytarabine, melphalan (BEAM) conditioning regimens for toxicity, engraftment kinetics, and efficacy in 139 patients undergoing autologous hematopoietic stem cell tr...
Author:Tapan Saikia , Shruti Agrawal ...
Data Source:[J].International Journal of Hematology(IF 1.681), 2009, Vol.89 (5), pp.664-672Springer
Abstract:Abstract(#br)Resistance and intolerance to imatinib are of particular clinical relevance to Asian patients because of their lower body surface area. Dasatinib is 325-fold more potent than imatinib in inhibiting BCR-ABL in vitro and is indicated for the treatment of chronic myeloi...
Author:Tapan Saikia , Chandrika Nair ...
Data Source:[J].Leukemia & Lymphoma(IF 2.301), 1990, Vol.1 (3-4), pp.271-273Informa Healthcare
Abstract:A patient suffering from chronic immune thrombocytopenia developing B-cell chronic lymphocytic leukemia seventeen years later, is reported. The possible mechanisms of association between the two disorders are discussed.
Author:Tapan Saikia , Chandrika Nair ...
Data Source:[J].Leukemia & Lymphoma(IF 2.301), 1990, Vol.2 (5), pp.307-316Informa Healthcare
Abstract:A retrospective clinical and histopathological analysis was performed of 1371 patients with Non-Hodgkin's lymphomas presenting between January 1981 and December 1985. Pathologic material was reviewed and classified according to the modified Rappaport classification. The most comm...

Being retrieved, please wait for a moment...

International Cooperation:cnki.scholar@cnki.net, +86-10-82896619   Feedback:scholar@cnki.net

×